Free Trial

Checkpoint Therapeutics (CKPT) Insider Trading & Ownership

Checkpoint Therapeutics logo
$3.75 +0.38 (+11.28%)
(As of 12/20/2024 05:51 PM ET)

Checkpoint Therapeutics (NASDAQ:CKPT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.10%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
2
Amount Of
Insider Selling
(Last 12 Months)
$1.95 M
Get CKPT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Checkpoint Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

CKPT Insider Buying and Selling by Quarter

Checkpoint Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2024James F Oliviero IIICEOSell220,230$3.38$744,377.40  
12/18/2024William Garrett GrayCFOSell268,432$4.01$1,076,412.32  
6/26/2024James F Oliviero IIICEOSell24,610$2.05$50,450.50  
6/26/2024William Garrett GrayCFOSell13,038$2.06$26,858.28  
2/28/2024James F Oliviero IIICEOSell5,894$2.06$12,141.64  
2/28/2024William Garrett GrayCFOSell2,035$2.07$4,212.45  
2/1/2024James F Oliviero IIICEOSell11,900$2.01$23,919.00  
2/1/2024William Garrett GrayCFOSell4,115$1.95$8,024.25  
(Data available from 1/1/2013 forward)

CKPT Insider Trading Activity - Frequently Asked Questions

The list of insiders at Checkpoint Therapeutics includes James F Oliviero III, and William Garrett Gray. Learn more on insiders at CKPT.

2.10% of Checkpoint Therapeutics stock is owned by insiders. Learn more on CKPT's insider holdings.

The following insiders have sold CKPT shares in the last 24 months: James F Oliviero III ($958,811.46), and William Garrett Gray ($1,170,030.70).

Insiders have sold a total of 585,880 Checkpoint Therapeutics shares in the last 24 months for a total of $2,128,842.16 sold.

Checkpoint Therapeutics Key Executives



This page (NASDAQ:CKPT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners